Please ensure Javascript is enabled for purposes of website accessibility

Here's How Novavax's Vaccine Stacks Up Against Moderna's and Pfizer's

By Adria Cimino - Feb 4, 2021 at 6:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can Novavax handle new coronavirus strains better than its rivals?

Novavax (NVAX -7.50%) shares climbed 2,700% last year as investors bet on the biotech company's investigational coronavirus vaccine. But the share price's story doesn't end there. Last week, the stock soared nearly 65% in just one trading session. What prompted such a jump? Novavax said its vaccine candidate was effective against the U.K. and South African strains of the virus in clinical trials. This was welcome news given one of the biggest worries these days -- that currently available vaccines won't hold up against these new strains. The company also reported phase 3 efficacy data concerning the older version of SARS-CoV-2.

You're probably asking yourself whether all of this offers Novavax an advantage over its more advanced rivals, Moderna (MRNA -1.20%) and Pfizer (PFE 1.50%). The U.S. Food and Drug Administration (FDA) offered their vaccines Emergency Use Authorization (EUA) late in 2020. Let's take a closer look at three key points to see how Novavax measures up.

A healthcare professional's hands hold two vials labeled Vaccine: COVID-19.

Image source: Getty Images.

1. Efficacy

A first glance, general efficacy shows Novavax's candidate lagging behind those of its commercialized rivals. Moderna and Pfizer reported efficacy of 94.1% and 95%, respectively, for their vaccines. Like Novavax's candidate, these vaccines both involve two doses, and full efficacy kicks in after the second dose.

Novavax reported 89.3% efficacy. But here's one important factor to keep in mind: Novavax's phase 3 trial took place in the United Kingdom -- home of the U.K. strain. And the U.K. strain has become more and more prevalent both there and elsewhere. Moderna and Pfizer generated their trial data before the newer variants of concern had gained ground. Their vaccines were primarily fighting the virus they were designed to fight: the original strain of SARS-CoV-2.

Novavax's vaccine -- like those of Moderna and Pfizer -- also was designed to combat the first version of the novel coronavirus; it's clear that efficacy will be higher when faced only with that version. In fact, Novavax calculated its candidate's efficacy against the earlier coronavirus at 95.6%.

2. New strains

Let's talk about new strains of the virus. Moderna and Pfizer have said their vaccines can handle the newer variants.

Moderna performed in vitro studies with blood serum from those vaccinated and found neutralizing antibody levels remained about the same when the U.K. strain was introduced. The South African strain resulted in a sixfold decline in antibody levels -- but they still remained high enough to maintain protection. Pfizer, in a similar in vitro test, introduced engineered viruses with key mutations from the U.K. and South African strains. The company's findings echoed those of Moderna.

As for Novavax, its investigational vaccine actually confronted these new strains during clinical studies rather than during in vitro testing. The company said its vaccine candidate was 85.6% efficacious against the U.K. strain in the U.K. phase 3 trial. In South Africa, a phase 2b trial demonstrated 60% efficacy against SARS-CoV-2 -- and about 90% of cases detected in the trial were of the South African strain. (This includes only HIV-negative trial participants.) This strain contains a mutation that helps it escape antibodies produced post-vaccination. Novavax's vaccine candidate demonstrated some protection against this variant -- and even some protection is welcome.

3. Severe disease

It's difficult to make a firm statement on severe disease due to the difference in trial size among the three companies, though Moderna and Novavax have an edge so far. Both companies reported no cases of severe coronavirus among those who received their vaccines in phase 3. Pfizer, however, reported one case of severe COVID-19 in a vaccinated trial participant.

Here's how the numbers look:

Company Trial Participants COVID-19 Cases Cases in Vaccine Group Severe Cases in Vaccine Group
Moderna 30,000 196 11 0
Novavax 15,000 62 6 0
Pfizer 43,000+ 170 8 1

Data source: Company press releases. Table by Author.

Why is prevention of severe disease so important? Severe disease is what leads to hospitalization, complications, and even death -- so one of the biggest goals of vaccination is to prevent extreme illness. A vaccine that could fully protect against this over time could clearly take market leadership.

So, how do things look for Novavax?

Looking at overall efficacy against the original SARS-CoV-2 virus, Novavax is on par with Moderna and Pfizer. As more and more data are collected from the trials, the numbers may shift slightly. But all three so far have reached more than 94% efficacy against the original strain. And that's positive news.

Novavax has tackled new strains in the real world and showed its candidate can hold up. However, it's possible that the Moderna and Pfizer vaccines, if also tested now in the U.K. and South Africa, would produce similar results. After all, their in vitro tests were encouraging.

As for preventing severe disease, Novavax and Moderna are leading in this area.

Overall, I would say Novavax may be on its way to becoming one of the strongest players. The biotech company clearly could enter the market on the same footing as its more advanced rivals. And that means billions of dollars in revenue it's hoping for are looking more and more likely.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$48.00 (-7.50%) $-3.89
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.67 (1.50%) $0.75
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.26 (-1.20%) $-1.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.